Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment
Abstract
1. Introduction
2. Results
3. Discussion
4. Conclusions
5. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hanno, P.M.; Sant, G.R. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology 2001, 57, 2–6. [Google Scholar] [CrossRef] [PubMed]
- Payne, C.K.; Mosbaugh, P.G.; Forrest, J.B.; Evans, R.J.; Whitmore, K.E.; Antoci, J.P.; Perez-Marrero, R.; Jacoby, K.; Diokno, A.C.; O’Reilly, K.J.; et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: A randomized, double-blind, placebo controlled trial. J. Urol. 2005, 173, 1590–1594. [Google Scholar] [CrossRef] [PubMed]
- Nickel, J.C.; Barkin, J.; Forrest, J.; Mosbaugh, P.G.; Hernandez-Graulau, J.; Kaufman, D.; Lloyd, K.; Evans, R.J.; Parsons, C.L.; Atkinson, L.E. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005, 65, 654–658. [Google Scholar] [CrossRef] [PubMed]
- Sant, G.; Propert, K.; Hanno, P.; Burks, D.; Culkin, D.; Diokno, A.; Hardy, C.; Landis, J.R.; Mayer, R.; Madigan, R.; et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J. Urol. 2003, 170, 810–815. [Google Scholar] [CrossRef]
- Hanno, P.M.; Buehler, J.; Wein, A.J. Use of amitriptyline in the treatment of interstitial cystitis. J. Urol. 1989, 141, 846–848. [Google Scholar] [CrossRef] [PubMed]
- Sairanen, J.; Forsell, T.; Ruutu, M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J. Urol. 2004, 171, 2138–2141. [Google Scholar] [CrossRef] [PubMed]
- Keay, S.; Zhang, C.-O.; Kagen, D.; Hise, M.; Jacobs, S.; Hebel, J.; Gordon, D.; Whitmore, K.; Bodison, S.; Warren, J. Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. J. Urol. 1997, 158, 1983–1988. [Google Scholar] [CrossRef]
- Tomaszewski, J.E.; Landis, J.; Russack, V.; Williams, T.M.; Wang, L.-P.; Hardy, C.; Brensinger, C.; Matthews, Y.L.; Abele, S.T.; Kusek, J.W.; et al. Biopsy features are associated with primary symptoms in interstitial cystitis: Results from the interstitial cystitis database study. Urology 2001, 57, 67–81. [Google Scholar] [CrossRef]
- Brady, C.; Apostolidis, A.; Harper, M.; Yiangou, Y.; Beckett, A.; Jacques, T.; Freeman, A.; Scaravilli, F.; Fowler, C.; Anand, P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int. 2004, 93, 770–776. [Google Scholar] [CrossRef]
- Ikeda, Y.; Zabbarova, I.V.; Birder, L.A.; de Groat, W.C.; McCarthy, C.J.; Hanna-Mitchell, A.T.; Kanai, A.J. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur. Urol. 2012, 62, 1157–1164. [Google Scholar] [CrossRef]
- Lin, C.C.; Huang, Y.C.; Lee, W.C.; Chuang, Y.C. New frontiers or the treatment of interstitial cystitis/bladder pain syndrome-Focused on stem cells, platelet-rich plasma, and low-energy shock wave. Int. Neurourol. J. 2020, 24, 211–221. [Google Scholar] [CrossRef]
- Jhang, J.-F.; Jiang, Y.-H.; Hsu, Y.-H.; Ho, H.-C.; A Birder, L.; Lin, T.-Y.; Kuo, H.-C. Improved urothelial cell proliferation, cytoskeleton and barrier function protein expression in the patients with interstitial cystitis/bladder pain syndrome after intravesical platelet-rich plasma injection. Int. Neurourol. J. 2022, 26, S57–S67. [Google Scholar] [CrossRef] [PubMed]
- Abrar, M.; Pindoria, N.; Malde, S.; Chancellor, M.; DeRidder, D.; Sahai, A. Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: A systematic review. Eur. Urol. Focus 2021, 7, 1448–1467. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.-H.; Jhang, J.-F.; Lin, T.-Y.; Ho, H.-C.; Hsu, Y.-H.; Kuo, H.-C. Therapeutic efficacy of intravesical platelet-rich plasma injections for interstitial cystitis/bladder pain syndrome-A comparative study of different injection number, additives and concentrations. Front. Pharmacol. 2022, 13, 853776. [Google Scholar] [CrossRef] [PubMed]
- Cockayne, D.A.; Hamilton, S.G.; Zhu, Q.-M.; Dunn, P.M.; Zhong, Y.; Novakovic, S.; Malmberg, A.B.; Cain, G.; Berson, A.; Kassotakis, L.; et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000, 407, 1011–1015. [Google Scholar] [CrossRef]
- Çayan, S.; Coşkun, B.; Bozlu, M.; Acar, D.; Akbay, E.; Ulusoy, E. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol. Res. 2003, 30, 399–404. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.-C.; Jiang, Y.-H.; Tsai, Y.-C.; Kuo, Y.-C. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment-A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn. 2016, 35, 609–614. [Google Scholar] [CrossRef]
- Steers, W.D.; Tuttle, J.B. Mechanisms of disease: The role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Pract. Urol. 2006, 3, 101–110. [Google Scholar] [CrossRef]
- Kuo, H.C. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Phys. 2013, 16, E15–E23. [Google Scholar] [CrossRef]
- Smith, C.P.; Radziszewski, P.; Borkowski, A.; Somogyi, G.T.; Boone, T.B.; Chancellor, M.B. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004, 64, 871–875, discussion 875. [Google Scholar] [CrossRef]
- Giannantoni, A.; Porena, M.; Costantini, E.; Zucchi, A.; Mearini, L.; Mearini, E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J. Urol. 2008, 179, 1031–1034. [Google Scholar] [CrossRef]
- Hanno, P.M.; Erickson, D.; Moldwin, R.; Faraday, M.M. American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J. Urol. 2015, 193, 1545–1553. [Google Scholar] [CrossRef]
- Lee, C.L.; Kuo, H.C. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins 2015, 7, 4283–4293. [Google Scholar] [CrossRef]
- Shie, J.H.; Liu, H.T.; Wang, Y.S.; Kuo, H.C. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int. 2013, 111, 638–646. [Google Scholar] [CrossRef]
- Mussano, F.; Genova, T.; Munaron, L.; Petrillo, S.; Erovigni, F.; Carossa, S. Cytokine, chemokine, and growth factor profile of platelet-rich plasma. Platelets 2016, 27, 467–471. [Google Scholar] [CrossRef]
- Amable, P.R.; Carias, R.B.V.; Teixeira, M.V.T.; da Cruz Pacheco, Í.; Amaral, R.J.F.C.D.; Granjeiro, J.M.; Borojevic, R. Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. Stem. Cell Res. Ther. 2013, 4, 67. [Google Scholar] [CrossRef]
- Wang, B.; Geng, Q.; Hu, J.; Shao, J.; Ruan, J.; Zheng, J. Platelet-rich plasma reduces skin flap inflammatory cells infiltration and improves survival rates through induction of angiogenesis: An experiment in rabbits. J. Plast. Surg. Hand Surg. 2016, 50, 239–245. [Google Scholar] [CrossRef]
- Jhang, J.; Lin, T.; Kuo, H. Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment–A prospective clinical trial. Neurourol. Urodyn. 2019, 38, 703–709. [Google Scholar] [CrossRef]
- Jiang, Y.-H.; Kuo, Y.-C.; Jhang, J.-F.; Lee, C.-L.; Hsu, Y.-H.; Ho, H.-C.; Kuo, H.-C. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci. Rep. 2020, 10, 15218. [Google Scholar] [CrossRef]
- Lee, Y.-K.; Jiang, Y.-H.; Jhang, J.-F.; Ho, H.-C.; Kuo, H.-C. Changes in the ultrastructure of the bladder urothelium in patients with interstitial cystitis after intravesical injections of platelet-rich plasma. Biomedicines 2022, 10, 1182. [Google Scholar] [CrossRef]
- Kuo, Y.C.; Kuo, H.C. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis-Different mechanisms of action of Botox on bladder dysfunction? Toxins 2016, 8, 75. [Google Scholar] [CrossRef]
- Homma, Y.; Akiyama, Y.; Tomoe, H.; Furuta, A.; Ueda, T.; Maeda, D.; Lin, A.T.; Kuo, H.-C.; Lee, M.-H.; Oh, S.-J.; et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2020, 27, 578–589. [Google Scholar] [CrossRef]
- Hanno, P.-M.; Landis, J.-R.; Matthews-Cook, Y.; Kusek, J.; Nyberg, L., Jr. The diagnosis of interstitial cystitis revisited: Lessons learned from the National Institute of Health Interstitial Cystitis Database study. J. Urol. 1999, 161, 553–557. [Google Scholar] [CrossRef]
- Parsons, C.L.; Benson, G.; Childs, S.J.; Hanno, P.; Sant, G.R.; Webster, G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol. 1993, 150, 845–848. [Google Scholar] [CrossRef]
- Lubeck, D.P.; Whitmore, K.; Sant, G.R.; Alvarez-Horine, S.; Lai, C. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 2001, 57, 62–66. [Google Scholar] [CrossRef]
- Gülpınar, O.; Kayış, A.; Süer, E.; Gökçe, M.İ.; Güçlü, A.G.; Arıkan, N. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can. Urol. Assoc. J. 2014, 8, E610–E614. [Google Scholar] [CrossRef][Green Version]
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; Van Kerrebroeck, P.; Victor, A.; Wein, A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol. Urodyn. 2002, 21, 167–178. [Google Scholar] [CrossRef]
- Parsons, C.L.; Greenberger, M.; Gabal, L.; Bidair, M.; Barme, G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J. Urol. 1998, 159, 1862–1866. [Google Scholar] [CrossRef]
PRP (n = 30) | BoNT-A (n = 26) | p-Value | |
---|---|---|---|
Age (years) | 52.57 ± 11.08 | 49.19 ± 17.03 | 0.392 |
ICSI | 12.57 ± 4.43 | 13.15 ± 4.15 | 0.613 |
ICPI | 11.63 ± 3.21 | 12.23 ± 3.23 | 0.492 |
VAS | 3.57 ± 3.14 | 5.35 ± 3.02 | 0.036 |
Frequency | 11.70 ± 6.39 | 13.95 ± 8.35 | 0.260 |
Nocturia | 3.28 ± 1.59 | 3.77 ± 5.33 | 0.651 |
FBC (mL) | 255.83 ± 126.74 | 264.16 ± 103.70 | 0.793 |
Qmax (mL/s) | 13.17 ± 7.01 | 16.54 ± 9.60 | 0.136 |
Volume (mL) | 192.43 ± 109.65 | 238.38 ± 112.70 | 0.128 |
PVR (mL) | 22.97 ± 45.04 | 21.73 ± 35.38 | 0.911 |
MBC (mL) | 768.33 ± 173.94 | 728.40 ± 219.94 | 0.455 |
Glomerulation | 1.37 ± 0.89 | 1.42 ± 0.93 | 0.841 |
Ulcer | 0 (0.0%) | 2 (7.7%) | 0.211 |
Duration (years) | 10.27 ± 8.85 | 8.92 ± 10.26 | 0.601 |
All (n = 56) | PRP (n = 30) | BoNT-A (n = 26) | p-Value | ||
---|---|---|---|---|---|
ICSI | BL | 12.84 ± 4.27 | 12.57 ± 4.43 | 13.15 ± 4.15 | |
1M | 9.95 ± 4.35 * | 9.43 ± 3.32 * | 10.54 ± 5.30 * | 0.616 | |
3M | 9.55 ± 4.16 * | 9.57 ± 3.66 * | 9.54 ± 4.75 * | 0.598 | |
6M | 9.00 ± 4.21 * | 8.33 ± 4.40 * | 9.77 ± 3.92 * | 0.410 | |
ICPI | BL | 11.91 ± 3.20 | 11.63 ± 3.21 | 12.23 ± 3.23 | |
1M | 9.20 ± 4.26 * | 8.93 ± 3.54 * | 9.50 ± 5.02 * | 0.975 | |
3M | 8.50 ± 3.69 * | 8.87 ± 3.21 * | 8.08 ± 4.20 * | 0.137 | |
6M | 8.73 ± 3.97 * | 8.60 ± 4.06 * | 8.88 ± 3.94 * | 0.781 | |
VAS | BL | 4.39 ± 3.18 | 3.57 ± 3.14 | 5.35 ± 3.02 | |
1M | 4.27 ± 3.11 | 4.00 ± 3.22 | 4.58 ± 3.02 | 0.062 | |
3M | 3.38 ± 2.90 * | 3.20 ± 3.01 | 3.58 ± 2.80 * | 0.068 | |
6M | 3.66 ± 3.06 * | 3.17 ± 3.18 | 4.23 ± 2.87 * | 0.239 | |
GRA | 1M | 0.84 ± 1.16 | 0.73 ± 1.08 | 0.96 ± 1.25 | |
3M | 0.89 ± 1.65 | 0.83 ± 1.58 | 0.96 ± 1.75 | 0.840 | |
6M | 1.36 ± 1.55 * | 1.53 ± 1.20 * | 1.15 ± 1.89 | 0.227 |
All (n= 56) | PRP (n= 30) | BoNT-A (n = 26) | p-Value | ||
---|---|---|---|---|---|
Frequency | BL | 12.74 ± 7.38 | 11.70 ± 6.39 | 13.95 ± 8.35 | |
1M | 11.40 ± 5.83 | 10.88 ± 4.98 | 11.99 ± 6.73 * | 0.475 | |
3M | 12.09 ± 6.48 | 10.77 ± 4.18 | 13.62 ± 8.21 | 0.729 | |
6M | 11.72 ± 5.63 | 10.95 ± 4.08 | 12.60 ± 6.99 | 0.694 | |
Nocturia | BL | 3.51 ± 3.78 | 3.28 ± 1.59 | 3.77 ± 5.33 | |
1M | 2.74 ± 3.00 | 2.55 ± 1.50 * | 2.97 ± 4.13 | 0.936 | |
3M | 2.63 ± 3.19 * | 2.22 ± 1.42 * | 309 ± 4.43 | 0.484 | |
6M | 2.57 ± 3.06 * | 2.35 ± 1.80 * | 2.83 ± 4.08 | 0.977 | |
FBC | BL | 259 ± 116 | 256 ± 127 | 264 ± 104 | |
1M | 283 ± 123 * | 276 ± 124 | 292 ± 125 | 0.783 | |
3M | 299 ± 126 * | 303 ± 135 * | 295 ± 118 | 0.935 | |
6M | 314 ± 138 * | 305 ± 136 * | 325 ± 142 | 0.465 | |
Qmax | BL | 14.73 ± 8.41 | 13.17 ± 7.01 | 16.54 ± 9.60 | |
1M | 14.74 ± 9.61 | 13.76 ± 8.02 | 15.88 ± 11.23 | 0.548 | |
3M | 16.04 ± 9.49 | 16.87 ± 10.48 | 15.10 ± 8.29 | 0.043 | |
6M | 15.98 ± 10.08 | 15.93 ± 10.80 | 16.03 ± 9.40 | 0.188 | |
Volume | BL | 214 ± 112 | 192 ± 110 | 238 ± 113 | |
1M | 207 ± 132 | 196 ± 123 | 218 ± 143 | 0.425 | |
3M | 212 ± 106 | 199 ± 93.9 | 227 ± 118 | 0.512 | |
6M | 232 ± 114 | 218 ± 114 | 248 ± 115 | 0.608 | |
PVR | BL | 22.39 ± 40.49 | 22.97 ± 45.04 | 21.73 ± 35.38 | |
1M | 39.88 ± 56.78 * | 25.97 ± 37.95 | 55.92 ± 70.16 * | 0.045 | |
3M | 34.46 ± 50.64 | 21.70 ± 27.06 | 49.19 ± 66.11 * | 0.070 | |
6M | 43.79 ± 78.38 * | 40.97 ± 88.59 | 47.04 ± 66.26 * | 0.735 |
PRP (n = 30) | BoNT-A (n = 26) | p-Value | |
---|---|---|---|
1M GRA ≥ 2 | 5 (16.7%) | 9 (34.6%) | 0.122 |
3M GRA ≥ 2 | 12 (40.0%) | 10 (38.5%) | 0.906 |
6M GRA ≥ 2 | 14 (46.7%) | 13 (50.0%) | 0.803 |
AE-Dysuria | 1 (3.3%) | 5 (19.2%) | 0.086 |
AE-UTI | 0 (0.0%) | 4 (15.4%) | 0.041 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jhang, J.-F.; Yu, W.-R.; Kuo, H.-C. Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment. Toxins 2023, 15, 121. https://doi.org/10.3390/toxins15020121
Jhang J-F, Yu W-R, Kuo H-C. Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment. Toxins. 2023; 15(2):121. https://doi.org/10.3390/toxins15020121
Chicago/Turabian StyleJhang, Jia-Fong, Wan-Ru Yu, and Hann-Chorng Kuo. 2023. "Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment" Toxins 15, no. 2: 121. https://doi.org/10.3390/toxins15020121
APA StyleJhang, J.-F., Yu, W.-R., & Kuo, H.-C. (2023). Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment. Toxins, 15(2), 121. https://doi.org/10.3390/toxins15020121